- Business Wire•2 days ago
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2017 on Friday, May 5, 2017, before the U.S.
- Accesswire•2 days ago
LONDON, UK / ACCESSWIRE / April 27, 2017 / Active Wall St. blog coverage looks at the headline from The Medicines Co. (NASDAQ: MDCO ) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ). On April 26, 2017, ...
- Business Wire•3 days ago
Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today final 24-month results from its Phase 2 open-label extension study of patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis.
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||48.33 x 200|
|Ask||57.39 x 200|
|Day's Range||51.38 - 53.66|
|52 Week Range||31.38 - 80.11|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|